61:
76:
originating in a 43-year-old caucasian female. The cell line over-expresses the HER2 gene product, which has been implicated in several breast cancer proliferation pathways. The SkBr3 cell line is autologous (derived from the same patient) with the AU565 cell line. The cells are considered
237:"Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor"
45:
333:"HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment"
140:
118:
97:
treatment resistance to HER2-overexpressing breast cancers. The cell line has also been examined for applications in
397:
284:"An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting"
402:
81:
1. They are known to grow in grape-like clusters with an invasive phenotype resembling that of the cells
60:
264:
362:
313:
256:
217:
352:
344:
303:
295:
248:
207:
197:
69:
236:
78:
357:
332:
308:
283:
212:
185:
73:
391:
38:
106:
268:
109:, and HER2-based cancer therapies in context of microenvironment fluctuations.
162:
348:
94:
41:
366:
317:
260:
252:
221:
299:
102:
382:
48:
in 1970 that is used in therapeutic research, especially in context of
98:
17:
202:
59:
49:
93:
SkBr3 cells have been used in studies seeking to overcome
186:"Choosing the right cell line for breast cancer research"
184:
Holliday, Deborah L; Speirs, Valerie (12 August 2011).
141:"SK-BR-3: Human Breast Cancer Cell Line (ATCC HTB-30)"
64:
The HER2 gene product is over-expressed in SkBr3 cells
235:Tseng, Ping-Hui; et al. (November 2006).
8:
331:Weigelt, Britta; et al. (1 July 2011).
282:Cao, Jian; et al. (2 November 2016).
356:
307:
211:
201:
143:. Memorial Sloan-Kettering Cancer Center
135:
133:
129:
46:Memorial Sloan–Kettering Cancer Center
7:
337:Breast Cancer Research and Treatment
25:
119:List of breast cancer cell lines
68:SkBr3 cells were derived from a
1:
27:Human breast cancer cell line
383:Cellosaurus entry for SkBr3
56:History and characteristics
419:
349:10.1007/s10549-009-0502-2
99:CRISPR/Cas9 gene editing
288:Nucleic Acids Research
253:10.1124/mol.106.023911
241:Molecular Pharmacology
190:Breast Cancer Research
65:
89:Research applications
63:
300:10.1093/nar/gkw660
66:
16:(Redirected from
410:
398:Human cell lines
371:
370:
360:
328:
322:
321:
311:
279:
273:
272:
247:(5): 1534–1541.
232:
226:
225:
215:
205:
181:
175:
174:
172:
170:
159:
153:
152:
150:
148:
137:
70:pleural effusion
44:isolated by the
21:
418:
417:
413:
412:
411:
409:
408:
407:
388:
387:
379:
374:
330:
329:
325:
281:
280:
276:
234:
233:
229:
203:10.1186/bcr2889
183:
182:
178:
168:
166:
163:"SK-BR-3 cells"
161:
160:
156:
146:
144:
139:
138:
131:
127:
115:
91:
79:biosafety level
58:
33:(also known as
28:
23:
22:
15:
12:
11:
5:
416:
414:
406:
405:
400:
390:
389:
386:
385:
378:
377:External links
375:
373:
372:
323:
274:
227:
176:
154:
128:
126:
123:
122:
121:
114:
111:
105:resistance in
90:
87:
74:adenocarcinoma
57:
54:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
415:
404:
403:Breast cancer
401:
399:
396:
395:
393:
384:
381:
380:
376:
368:
364:
359:
354:
350:
346:
342:
338:
334:
327:
324:
319:
315:
310:
305:
301:
297:
293:
289:
285:
278:
275:
270:
266:
262:
258:
254:
250:
246:
242:
238:
231:
228:
223:
219:
214:
209:
204:
199:
195:
191:
187:
180:
177:
164:
158:
155:
142:
136:
134:
130:
124:
120:
117:
116:
112:
110:
108:
107:transfections
104:
100:
96:
88:
86:
84:
80:
75:
71:
62:
55:
53:
51:
47:
43:
40:
39:breast cancer
37:) is a human
36:
32:
19:
343:(1): 35–43.
340:
336:
326:
294:(19): e149.
291:
287:
277:
244:
240:
230:
196:(215): 215.
193:
189:
179:
167:. Retrieved
157:
145:. Retrieved
92:
82:
67:
34:
30:
29:
165:. Addex Bio
52:targeting.
392:Categories
125:References
72:due to an
95:Herceptin
42:cell line
367:19701706
318:27458201
261:16887935
222:21884641
113:See also
103:antibody
358:2935800
309:5100567
213:3236329
169:18 June
147:18 June
83:in vivo
35:SK-BR-3
365:
355:
316:
306:
269:222111
267:
259:
220:
210:
265:S2CID
31:SkBr3
18:SkBr3
363:PMID
314:PMID
257:PMID
218:PMID
171:2018
149:2018
50:HER2
353:PMC
345:doi
341:122
304:PMC
296:doi
249:doi
208:PMC
198:doi
394::
361:.
351:.
339:.
335:.
312:.
302:.
292:44
290:.
286:.
263:.
255:.
245:70
243:.
239:.
216:.
206:.
194:13
192:.
188:.
132:^
101:,
85:.
369:.
347::
320:.
298::
271:.
251::
224:.
200::
173:.
151:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
